Symbols

ALT

Altimmune·NASDAQ

--(--)

ALT fundamentals

ALT Q4 2025 Earnings

Altimmune (ALT) released its earnings on Mar 5, 2026: revenue was 26.00K (YoY +420.00%), beat estimates; EPS was -0.27 (YoY +18.18%), missed estimates.

Revenue / YoY

26.00K

+420.00%

EPS / YoY

-0.27

+18.18%

Report date

Mar 5, 2026

ALT Earnings Call Summary for Q4,2025

Phase III Trial Initiation: FDA-aligned design with 990 patients (F2/F3) targeting MASH resolution and fibrosis improvement, powered for 1.8 mg dose.
FDA Breakthrough Designation: Pemvidutide recognized for potential to substantially improve MASH outcomes.
Capital Strength: $340 million cash runway after $75 million capital raise, supporting Phase III execution into 2028.
Tolerability Differentiation: Simple 1-2 step titration and 7.5% weight loss at 1.8 mg dose in Phase IIb, with low discontinuation rates.
Competitive Edge: Dual glucagon/GLP-1 mechanism addresses liver fat and metabolic drivers, with potential for lean muscle preservation.

Earnings

EPS

Revenue

Revenue & Expenses

ALT has released its 2025 Q4 earnings report, with revenue of 26.00K, reflecting a YoY change of 420.00%, and net profit of -27.36M, showing a YoY change of -18.02%. The Sankey diagram below clearly presents ALT's revenue sources and cost distribution.

Key Indicators

Altimmune (ALT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Altimmune (ALT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Altimmune (ALT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Altimmune (ALT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown